Evidence map›Paper›PMID 40478921›Full record

ArticlePloS one2025

Overestimated cytotoxicity and underestimated whitening efficacy of glabridin: A result of its poor solubility in DMSO.

Haiyan Liu, Anning Wang, Xiaoyi Chen, Sen Hou, Anzhang Li

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haiyan LiuGuangzhou Fanzhirong Cosmetics Co., Ltd., Huangpu District, Guangzhou, Guangdong, China.
Anning WangGuangzhou Fanzhirong Cosmetics Co., Ltd., Huangpu District, Guangzhou, Guangdong, China.
Xiaoyi ChenGuangzhou Zhongkejian Technology Testing Co., Ltd., Guangzhou Fanzhirong Cosmetics Co. Ltd., Huangpu District, Guangzhou, Guangdong, China.
Sen HouGuangzhou Fanzhirong Cosmetics Co., Ltd., Huangpu District, Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0002-6871-4419
Anzhang LiGuangzhou Fanzhirong Cosmetics Co., Ltd., Huangpu District, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glabridin is widely used as a whitening agent in cosmetics, but its cytotoxicity remains a key concern in safety evaluations. In typical cytotoxicity assays, glabridin is dissolved in dimethyl sulfoxide (DMSO) before being added to the cell culture medium because it is insoluble in water. However, our study revealed that when the DMSO solution of glabridin was mixed with cell culture medium, glabridin was rapidly released due to its poor solubility in the DMSO/water mixture. The released glabridin rapidly formed crystals, which failed to enter cells. Consequently, the whitening efficacy of glabridin was reduced. Moreover, the glabridin crystals produced higher cytotoxicity, possibly due to the physical damage caused by their sharp crystalline structures. However, encapsulating glabridin in cyclodextrin (CD) can address these challenges, offering a better approach for glabridin cytotoxicity assays. The CD encapsulation method, compared to the DMSO solution method, not only decreased the cytotoxicity of glabridin but also increased its whitening efficacy. By comparing the efficacy of glabridin dissolved in DMSO and encapsulated in CD, we discovered that the reported cytotoxicity of glabridin may have been overestimated in previous cytotoxicity studies which used DMSO as a solvent, while its whitening efficacy may have been underestimated. These findings not only offer new insights for in vitro studies of glabridin-like reagents, but also facilitate the development of safer and more effective whitening products.

Indexed as

Dimethyl SulfoxideIsoflavonesPhenolsCell SurvivalCyclodextrinsHumansSolubilityCyclodextrinsDimethyl SulfoxideglabridinIsoflavonesPhenols

Identifiers

PMID40478921
PMCPMC12143567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.